| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
National Cancer Institute National Institutes of Health Bethesda, Maryland 20014
Data are reported on 2155 randomly selected synthetic compounds which failed the CCNSC primary screens. Most of the materials were tested against Sarcoma 180, Adenocarcinoma 755 and Leukemia L1210. Cell-culture cytotoxicity results for these materials are included.
1 Chief, Cancer Chemotherapy National Service Center.
2 Biologist, Screening Section, Cancer Chemotherapy National Service Center.
3 Assistant Chief, Cancer Chemotherapy National Service Center.
4 Arthur D. Little, Inc., Cambridge, Massachusetts.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |